$MBX News
Last published 1h ago
- 1h agoBLLNMBXOMDANorwest Announces $4 Billion Global, Multi-Stage FundBusiness WireMENLO PARK, Calif.--(BUSINESS WIRE)--Norwest, a global, multi-stage investment firm, today announced the close of Norwest 18, a $4 billion fund and the largest in the firm's 65-year history, bringing its total capital under management to $18 billion. The fund will support venture and growth equity investments across technology, healthcare, and consumer sectors in the U.S., India, and Israel, build ...
- 2d agoMBXMBX Biosciences, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 7.01 Item 9.01
- 2d agoMBXMBX Biosciences Reports Third Quarter 2026 Financial Results and Corporate HighlightsGlobeNewswireEnrollment in pivotal Phase 3 oPTimize trial of once-weekly canvuparatide underway 12-week MAD (Part C, Cohort 1) data for MBX 4291, a GLP-1/GIP co-agonist prodrug for obesity designed for once-monthly dosing, on track
- 2d agoMBXMBX Biosciences Reports Third Quarter 2026 Financial Results and Corporate HighlightsGlobeNewswireEnrollment in pivotal Phase 3 oPTimize trial of once-weekly canvuparatide underway
- 6d agoPNGAFMBXKLRAALT+1Federal Peptide Policy Shift Could Ignite a New Wave Of Growth Across the $164 Billion Peptide MarketGlobeNewswireNEW YORK, Nov. 05, 2026 (GLOBE NEWSWIRE) -- The federal government's October 30, 2026, decision could be a big deal for the peptide industry. HHS has signaled that it does not intend to pursue enforcement action
- 1mo agoMBXMBX Biosciences to Participate in Upcoming November Investor ConferencesGlobeNewswireCARMEL, Ind. and BURLINGTON, Mass., Oct. 13, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel
- 1mo agoMBXSTIFEL 2026 VIRTUAL CARDIOMETABOLIC FORUM - MBX BIOSCIENCES INCEarnings Call TranscriptsHi, good morning, everyone. It's our pleasure to have the management of MBX Biosciences here with us today. I have to apologize for the delay. We had some linking problems. So we have newly appointed CEO Steve Hoarder wi
- 1mo agoMBXSTIFEL 2026 VIRTUAL CARDIOMETABOLIC FORUM - MBX BIOSCIENCES INCEarnings Call TranscriptsHi, good morning, everyone. It's our pleasure to have the management of MBX Biosciences here with us today. I have to apologize for the delay. We had some linking problems. So we have newly appointed CEO Steve Hoarder wi
- 1mo agoMBXMBX Biosciences, Inc. - 1773729 - MBX BIOSCIENCES INCEarnings Call TranscriptsOkay, great. Good morning, everyone. Welcome to day three. We're saving the best for last year at the Morgan Stanley Conference. I'm Jason Russell, and it's a pleasure to welcome MBX to the stage. So, CEO Steve Herter, a
- 1mo agoMBXMBX Biosciences, Inc. - 1773729 - MBX BIOSCIENCES INCEarnings Call TranscriptsOkay, great. Good morning, everyone. Welcome to day three. We're saving the best for last year at the Morgan Stanley Conference. I'm Jason Russell, and it's a pleasure to welcome MBX to the stage. So, CEO Steve Herter, a
- 2mo agoMBXMBX Biosciences to Participate in Upcoming Investor ConferencesGlobeNewswireCARMEL, Ind., and BURLINGTON, Mass., Sept. 09, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of
- 2mo agoMBXMBX Biosciences Announces Appointment of Jeff Held as Chief Legal OfficerGlobeNewswireCARMEL, Ind. and BURLINGTON, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of
- 2mo agoMBXMBX Biosciences Announces First Patient Dosed in Pivotal Phase 3 oPTimize Trial of Once-Weekly Canvuparatide in Adults with HypoparathyroidismGlobeNewswirePivotal Phase 3 oPTimize trial design builds on positive Phase 2 Avail™ results and durable one-year clinical benefit Global registrational trial to enroll approximately 160 adults with HP to support once-weekly
- 3mo agoMBXMBX Biosciences Reports Second Quarter 2026 Financial Results and Corporate HighlightsGlobeNewswireOne-year data demonstrated sustained benefit of once-weekly canvuparatide as a potential PTH replacement therapy in chronic hypoparathyroidism; Phase 3 pivotal trial now recruiting Initial Phase 1 data for MBX 4291, a
- 3mo agoMBXARQTNAMSGNLXAttovia Therapeutics Appoints John W. Smither to Board of DirectorsGlobeNewswireSAN CARLOS, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- Attovia Therapeutics, Inc. ("Attovia" or the "Company"), a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for
- 4mo agoMBXMBX Biosciences Announces Executive Leadership Transition to Support the Company’s Next Phase of GrowthGlobeNewswireCARMEL, Ind. and BURLINGTON, Mass., July 13, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel
- 5mo agoMBXMBX Biosciences Conference CallMBX BIOSCIENCES INCEarnings Call TranscriptsGreetings, and welcome to the MBX Biosciences Business Update Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. If anyone should require op
- 5mo agoMBXMBX Biosciences Announces One-Year Data Demonstrating Sustained Benefit of Once-Weekly Canvuparatide as a Potential PTH Replacement Therapy in Chronic HypoparathyroidismGlobeNewswireResponder rate of 57% at one year in open-label extension (OLE) comparable to 63% at 12 weeks in Phase 2 Avail™ trial Results consistent with restoration of systemic PTH activity through serum calcium
- 5mo agoMBXJefferies Global Healthcare Conference - MBX BIOSCIENCES INCEarnings Call TranscriptsGood morning, everyone. Thanks for joining us. Welcome to day one of Jeffries Global Healthcare Conference. My name is Fiona. I cover speed cap biotech companies at Jeffries, and it is my greatest pleasure to welcome to
- 5mo agoMBXMBX Biosciences to Host Virtual Investor Event to Discuss Once-Weekly Canvuparatide Presentations at ENDO 2026GlobeNewswireCARMEL, Ind., June 01, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide
- 5mo agoMBXMBX Biosciences to Present at the Jefferies 2026 Global Healthcare Conference in New York CityGlobeNewswireCARMEL, Ind. and BURLINGTON, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel
- 6mo agoMBXMBX Biosciences Provides Obesity Portfolio Update Including Initial Phase 1 Data for MBX 4291 Supporting Potential for Once-Monthly DosingGlobeNewswirePreliminary blinded data from ongoing Phase 1 trial demonstrated mean weight loss of 7% (range 0-16%) at 8 weeks in first MAD Part B cohort (n=8, including 2 placebo) MBX 4291 generally well tolerated, only one event of
- 6mo agoMBXMBX Biosciences Reports First Quarter 2026 Financial Results and Corporate HighlightsGlobeNewswireResults from Phase 2 trial of once-weekly canvuparatide accepted for oral presentation at ENDO in June 2026 Phase 3 trial of once-weekly canvuparatide on track to initiate in Q3 2026 Appointment of Mark Soued as Chief
- 6mo agoMBXMBX Biosciences Announces Appointment of Mark Soued as Chief Commercial Officer and Inducement Grant AwardGlobeNewswireCARMEL, Ind. and BURLINGTON, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel
- 6mo agoMBXMBX Biosciences to Host In-Person and Virtual Obesity Day on May 11, 2026 to Discuss Expanding Obesity PortfolioGlobeNewswireCARMEL, Ind. and BURLINGTON, Mass., April 23, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel
- 7mo agoMBXMBX Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireCARMEL, Ind., April 03, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide
- 8mo agoMBXMBX Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate HighlightsGlobeNewswirePhase 3 trial of once-weekly canvuparatide remains on track to initiate in Q3 2026 following recently completed, successful End-of-Phase 2 meeting with FDA 12-week MAD Phase 1 data from MBX 4291 for obesity
- 8mo agoMBXBarclays 28th Annual Global Healthcare ConferenceMBX BIOSCIENCES INCEarnings Call TranscriptsHi, everyone. Good afternoon. Thanks so much for joining us here in Miami for the Barclays 28th Annual Global Healthcare Conference. Very happy to have MBX here with us today. I'm Ellie Murrow, one of the biotech analyst
- 8mo agoMBXMBX Biosciences Appoints Karen Basbaum as Chief Business OfficerGlobeNewswireCARMEL, Ind., March 10, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide
- 8mo agoMBXCORRECTING & REPLACING -- MBX Biosciences Announces Successful End-of-Phase 2 FDA Meeting and Provides Phase 3 Development Plan for Once-Weekly Canvuparatide for HypoparathyroidismGlobeNewswireIn the fourth paragraph, we are replacing milligrams with micrograms. The corrected press release follows. CARMEL, Ind., March 09, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage
- 8mo agoMBXMBX Biosciences Announces Successful End-of-Phase 2 FDA Meeting and Provides Phase 3 Development Plan for Once-Weekly Canvuparatide for HypoparathyroidismGlobeNewswireCARMEL, Ind., March 09, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide
- 8mo agoMBXMBX Biosciences to Participate in Upcoming March Investor ConferencesGlobeNewswireCARMEL, Ind., Feb. 23, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel precision peptide
- 9mo agoMBXMBX Biosciences to Participate in Upcoming Investor ConferencesGlobeNewswireCARMEL, Ind., Feb. 11, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel precision peptide
- 9mo agoMBXMBX Biosciences Appoints Laurie Stelzer to Board of Directors as Audit Committee ChairGlobeNewswireCARMEL, Ind., Jan. 22, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide
- 10mo agoMBXMBX Biosciences to Provide 2026 Outlook and Business Update at 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswireOne-year follow-up data from Phase 2 trial of once-weekly canvuparatide, a potential best-in-class therapy for hypoparathyroidism, anticipated in Q2 2026; Phase 3 initiation on track for Q3 2026 12-week data from Phase
- 11mo agoMBXMBX Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13GlobeNewswireCARMEL, Ind., Dec. 15, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the
- 11mo agoMBXMBX Biosciences to Participate in the 37th Annual Piper Sandler Healthcare ConferenceGlobeNewswireCARMEL, Ind., Nov. 18, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the
- 1y agoMBXMBX Biosciences Reports Third Quarter 2025 Financial Results and Recent Corporate HighlightsGlobeNewswireReported positive topline results from the Phase 2 Avail™ trial of once-weekly canvuparatide in hypoparathyroidism (HP) Completed upsized public offering, raising approximately $200 million in gross proceeds
- 1y agoMBXMBX Biosciences to Participate in November Investor ConferencesGlobeNewswireCARMEL, Ind., Oct. 20, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the
- 1y agoMBXMBX Biosciences to Participate in the Stifel 2025 Virtual Cardiometabolic ForumGlobeNewswireCARMEL, Ind., Sept. 29, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc.
- 1y agoMBXMBX Biosciences Announces Pricing of Upsized Public OfferingGlobeNewswireCARMEL, Ind., Sept. 24, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the
- 1y agoMBXMBX Biosciences Announces Proposed Public OfferingGlobeNewswireCARMEL, Ind., Sept. 22, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the
- 1y agoMBXMBX Biosciences Announces Once-Weekly Canvuparatide Achieved Primary Endpoint in Phase 2 Trial with 63% Responder Rate at 12 Weeks; 79% Responder Rate at 6 Months in Open-Label ExtensionGlobeNewswireStatistically significant responder rate achieved at 12 weeks with zero contribution from rescue therapy (PRN) and further improvement sustained in open-label extension (OLE) Positive findings in bone and kidney
- 1y agoMBXMBX Biosciences to Provide Topline Results from its Phase 2 Trial of Potential Once-Weekly Canvuparatide for Hypoparathyroidism (HP) on Monday, September 22GlobeNewswireCARMEL, Ind., Sept. 19, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the
- 1y agoMBXMBX Biosciences Doses First Participant in Phase 1 Trial of MBX 4291 for the Treatment of ObesityGlobeNewswireCARMEL, Ind., Sept. 04, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the
- 1y agoMBXMBX Biosciences Reports Second Quarter 2025 Financial Results and Recent Corporate HighlightsGlobeNewswireTopline results for the Phase 2 Avail™ trial of canvuparatide in hypoparathyroidism on track for Q3 2025 Imapextide (MBX 1416) Phase 2a trial initiation in patients with post-bariatric hypoglycemia anticipated
- 1y agoMBXMBX Biosciences Announces IND Submission of MBX 4291, its Long-acting GLP1/GIP Receptor Co-agonist Prodrug for the Treatment of ObesityGlobeNewswireGLP-1/GIP receptor co-agonist designed to be highly potent and for once-monthly administration based on MBX's novel PEP™ platform technology Phase 1 trial of MBX 4291 is expected to initiate in Q3 2025 CARMEL,
- 1y agoMBXMBX Biosciences to Present at the American Diabetes Association 85th Scientific SessionsGlobeNewswireCARMEL, Ind., June 10, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the
- 1y agoMBXMBX Biosciences to Participate in June Investor ConferencesGlobeNewswireCARMEL, Ind., May 20, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the
- 1y agoMBXMBX Biosciences Reports First Quarter 2025 Financial Results and Recent Corporate HighlightsGlobeNewswireTopline results for the Phase 2 Avail™ evaluating canvuparatide in patients with hypoparathyroidism expected in 3Q 2025 Investigational New Drug submission for MBX 4291 on track for 2Q 2025 $240.8 million in